

AGENDA

Thursday, October 24th

Parallel workshops 10:00-11:30

Workshop 1

**Clinical Genetics in Cardiomyopathies - Joint session with ESHG
(Auditorium: Aquarius / Taurus)**

Chairpersons: Ph. Charron, (Paris, FR), M. Macek, (Prague, CZ)

Clinical Utility Gene Cards: a bridge between clinical genetics and cardiology M. Macek, Prague, CZ

Clinical and genetic features of pediatric HCM J.P. Kaski, London, UK

Cascade screening in relatives J.R. Gimeno Blanes, Murcia, SP

Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with sarcomere thin filament gene mutations R. Coppini, Florence, IT

Workshop 2

**The clinical and diagnostic challenge of myocarditis
(Auditorium: Leo / Virgo)**

Chairpersons: A. Caforio, (Padua, IT), K. Klingel, (Tübingen, DE)

When to suspect myocarditis T. Paleček, Prague, CZ

How to interpret histology and Immunohistochemistry S. Pankuweit, Marburg, DE

How to reach the diagnosis of infectious myocarditis K. Klingel, Tübingen, DE

How to identify patients with adverse prognosis A. Caforio, Padua, IT

How to treat myocarditis: current knowledge and issues for future treatment trials B. Maisch, Marburg, DE

Coffee break 11:30-12:00

Parallel workshops 12:00-13:30

Workshop 3

Molecular genetics and cardiomyopathies - Joint session with ESHG

AGENDA

(Auditorium: Aquarius / Taurus)

Chairpersons: J. Mogensen, (Aarhus, DK), Y. Pinto, (Amsterdam, NL)

How to interpret a genetic result

Y. Pinto,
Amsterdam, NL

Is Next generation sequencing a revolution for our practice?

J. Mogensen,
Aarhus, DK

Capture based approach for large panels of genes, where are we?

B. Meder,
Heidelberg, DE

Application of (targeted) next generation sequencing (NGS) in clinical genetic diagnostics of cardiomyopathies

J. Jongbloed,
Groningen, NL

Workshop 4

Heart failure and exercise cardiopulmonary testing

(Auditorium: Leo / Virgo)

Chairpersons: A. Keren, (Jerusalem, IL), C. Rapezzi, (Bologna, IT)

Exercise cardiopulmonary stress testing - the basics

J. Radvanský,
Prague, CZ

Exercise cardiopulmonary stress testing - clinical applications

M. Matoulek,
Prague, CZ

The role of electrocardiogram in pre-participation screening in athletes

C Rapezzi,
Bologna, IT

Device monitoring of heart failure patients

A. Keren,
Jerusalem, IL

Biomarkers in heart failure and myocardial diseases

P. de Groote,
Lille, FR

Workshop 5

Clinical Genetics for Cardiomyopathies

(Auditorium: Tycho / Kepler)

Chairpersons: Y. Adler, (Ramat Gan, IL), A. Linhart, (Prague, CZ)

Acute and recurrent pericarditis

M. Imazio,
Turin, IT

Constrictive pericarditis

B. Maisch,
Marburg, DE

AGENDA

Cardiac tamponade

A. Ristić,
Belgrade, RS

Pericardial effusion

A. Brucato,
Bergamo, IT

Lunch 13:30-14:30

Plenary session 14:30-16:30

**Imaging in cardiomyopathies
Joint session with EACVI
(Auditorium: Meridian)**

Chairpersons: L. Badano, (Padua, IT), A. Linhart, (Prague, CZ)

Diastolic function in cardiomyopathies

T. Paleček,
Prague, CZ

**Deformation imaging to assess patients with suspect
cardiomyopathy**

L. Badano,
Padua, IT

Exercise echocardiography

A. Pantazis,
London, UK

The role of echocardiography in CRT

J. Marek,
Pittsburgh (PA), US

MRI in cardiomyopathies

S. Prasad,
London, UK

**Cardiac magnetic resonance imaging in children with
hypertrophic cardiomyopathy**

F. Raimondi,
Paris, FR

Coffee break 16:30-17:00

Plenary session 17:00-18:30

**Management of arrhythmias in cardiomyopathies
Joint session ČKS, DGK, EHRA
(Auditorium: Meridian)**

Chairpersons: J. Kautzner, (Prague, CZ), M. Táborský, (Olomouc, CZ)

**The role of imaging in sudden cardiac death stratification in
cardiomyopathies**

A. Linhart,
Prague, CZ

**ICD therapy in patients with cardiomyopathies - long-term
results and complications**

G. Hindricks,
Leipzig, DE

Catheter ablation of ventricular arrhythmias in patients with

J. Kautzner,

AGENDA

cardiomyopathies

Prague, CZ

Long-term results of remote monitoring of ICD patients with cardiomyopathies

M. Táborský,
Olomouc, CZ

Friday, October 25th

Plenary sessions – Auditorium Meridian

9:00 - 9:15

Congress opening 9:00 – 9:15

9:15 - 9:40

Featured lecture

**Next Generation Genetic Diagnostics: from the Tyrolean Iceman to routine care
A. Keller, Saarbrücken / Erlangen, DE**

9:40 - 11:10

**Metabolic and other pediatric cardiomyopathies
Joint session with EAPC**

Chairpersons: Ph. Charron, (Paris, FR), M. Gorenflo, (Heidelberg, DE)

Metabolic and storage cardiomyopathies

D. Bonnet,
Paris, FR

Heart and the RAS-MAPK signalling pathway

G. Limongelli,
Naples, IT

Mitochondrial cardiomyopathies

A. Serio,
Pavia, IT

Heart and Neuromuscular disorders

D. Duboc,
Paris, FR

Unrecognized secondary hemochromatosis

M. Benešová,
Prague, CZ

Coffee break 11:10 - 11:30

11:30 - 13:00

Metabolic cardiomyopathies - focus on Fabry disease

Chairpersons: P.M. Elliott, (London, UK), A. Linhart, (Prague, CZ)

AGENDA

Cardiac manifestations of Fabry disease – current insights	A. Linhart, Prague, CZ
Screening for Fabry disease	F. Cecchi, Florence, IT
ECG changes in Fabry disease - new aspects and clinical implications	M. Namdar, Lausanne, CH
Enzyme replacement therapy	C. Kampmann, Mainz, DE
The prevalence of Fabry cardiomyopathy in patients with unexplained left ventricular hypertrophy in Taiwan	Chin-Chan Lin, Tainan, TW
Endomyocardial biopsies in cardiomyopathy patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)	Wen-Chung Yu, Tai-Pei, TW

13:00 - 14:20

Arrhythmia management in heart failure and cardiomyopathies

Chairpersons: Y. Pinto, (Amsterdam, NL), A. Keren, (Jerusalem, IL)

Atrial fibrillation in hypertrophic and dilated cardiomyopathy – prognostic implications and current management concepts	I. Olivotto, Florence, IT
Results of RFA in substrate modification in cardiomyopathies	E. Gandjbakhch, Paris, FR
Acute management of arrhythmia in dilated cardiomyopathies	G. Stix, Vienna, AT
Predictors of non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy: a multicentric Portuguese study	E. Correia, Viseu, PT
Occurrence and characteristics of inappropriate Implantable Cardioverter- Defibrillator shocks out of clinical trials and their impact on mortality	I. Burazor, Nis, RS

Lunch 14:20 - 15:10

15:10 - 16:40

Pericardial diseases Contemporary management of pericardial effusion

Chairpersons: Y. Adler, (Ramat Gan, IL), M. Imazio, (Turin, IT)

Aetiology	B. Maisch, Marburg, DE
------------------	---------------------------

AGENDA

Diagnostic workup	M. Imazio, Turin, IT
Medical and Surgical therapies	A. Brucato, Bergamo, IT
Cardiac tamponade: position statement of the WG	A. Ristić, Belgrade, RS
Therapeutic pericardiocentesis guided by echocardiography only in noninvasive cardiology department – safety profile	R. Kočková, Prague, CZ

16:40 - 17:00

Featured lecture
PRKAG2 and Danon disease - what clinicians should know
J. Mogensen, Aarhus, DK

Coffee break 17:00-17:30

17:30 - 19:00

Hypertrophic cardiomyopathy
new insights in the pathophysiology, diagnosis and treatment

Chairpersons: F. Cecchi, (Florence, IT), H. Seggewiss, (Schweinfurt, DE)

Prevention of sudden cardiac death: time for an evidence based approach	P. Elliott, London, UK
Septal ablation - an option for every symptomatic patient with HOCM in the 21st century?	H. Seggewiss, Schweinfurt, DE
HCM phenotype beyond hypertrophy	I. Olivotto, Florence, IT
Myocardial fibrosis: pathology and potential therapeutic target	G. Limongelli, Naples, IT
Is clinical severity of traits in inherited heart disease fully determined by genetic background?	J. Jansweijer, Amsterdam, NL
Incremental diagnostic value of Whole Exome Sequencing in undefined cardiomyopathies	F. Girolami, Florence, IT
Ventricular arrhythmias are uncommon after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy	A. Rigopoulos, Schweinfurt, DE

AGENDA

Gala Dinner – Prague Castle 20:00 - 23:00

Saturday, October 26th

Plenary sessions – Auditorium Meridian

9:00 - 10:40

Inflammatory infectious and non-infectious cardiomyopathies

Chairpersons: K. Klingel, (Tübingen, DE), T. Paleček, (Prague, CZ)

Heart and HAART: two sides of the coin for HIV-associated cardiovascular disease

G. Barbaro,
Rome, IT

Borrelia infection and the development of dilated cardiomyopathy

P. Kuchynka,
Prague, CZ

Giant cell and eosinophilic myocarditis

A. Caforio,
Padua, IT

BSE-associated Prion-Amyloid Cardiomyopathy

M. Glatzel,
Hamburg, DE

Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role

S. Longhi,
Bologna, IT

10:40 - 11:00

Featured lecture

Sarcoidosis

P.M.Elliott, London, UK

Coffee break 11:00-11:20

11:20-12:40

Arrhythmogenic right ventricular dysplasia

Chairpersons: J.R. Gimeno Blanes, (Murcia, SP), J. Mogensen, (Aarhus, DK)

Genetics

J.P. Van Tintelen,
Groningen, NL

Non-invasive imaging

A. Pantazis,
London, UK

Risk stratification and clinical management of ARVC

W. McKenna,

AGENDA

London, UK

Clinical arrhythmic risk assessment of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC)	A. Protonotarios, Naxos, GR
--	--------------------------------

Arrhythmogenic right ventricular cardiomyopathy and heart transplantation due to severe heart failure	M. Graziosi, Bologna, IT
--	-----------------------------

12:40 - 13:40

Pregnancy and cardiomyopathies

Chairpersons: Ph. Charron, (Paris, FR), J. Krejčí, (Brno, CZ)

Peripartum cardiomyopathy	L.A. Blauwet, Rochester (MN), US
----------------------------------	-------------------------------------

Cardiac management of women with HCM	Ph. Charron, Paris, FR
---	---------------------------

Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy	van Spaendonck-Zwarts, Amsterdam, NL
---	---

Lunch 13:40-14:30

14:30 - 16:00

Myocarditis

Chairpersons: A. Caforio, (Padua, IT), S. Pankuweit, (Marburg, DE)

Clinically suspected and biopsy-proven myocarditis: what' s new in the Myocarditis Position Statement?	A. Caforio, Padua, IT
---	--------------------------

Infectious myocarditis (pathogens vs innocent bystanders): the state-of the art of molecular diagnosis	K. Klingel, Tübingen, DE
---	-----------------------------

State-of-art of antiviral therapy in inflammatory cardiomyopathy: when, how, for which patients.	H.P. Schultheiss, Berlin, DE
---	---------------------------------

Catheter ablation and epicardial substrate electroanatomical mapping in myocarditis with ventricular tachycardia: the new frontier?	G. Maccabelli, Milan, IT
--	-----------------------------

Markers of immune activation and apoptosis in endomyocardial biopsies of individuals with recent-onset dilated cardiomyopathy	M. Kubánek Prague, CZ
--	--------------------------

16:00 - 17:20

Hypertrophic cardiomyopathy and athlete's heart

Chairpersons: A. Anastasakis, (Athens, GR), A. Linhart, (Prague, CZ)

AGENDA

Normal physiological response to training and differentiation of physiological hypertrophy from hypertrophic cardiomyopathy	A. Anastasakis, Athens, GR
Difficulties in diagnosis of heart disease in athletes	A. Keren, Jerusalem, IL
All athletes should be screened with an ECG before sports participation	N. Sheikh, London, UK
Pro	W. McKenna, London, UK
Contra	
Prevalence and outcome of abnormal electrocardiograms in highly-trained athletes using modern ECG criteria. A 12-year follow-up prospective study.	A. Steriotis, Athens, GR

Coffee break 17:20-17:40
17:40 - 19:00

Pericardial diseases Update on the management after 2004 ESC guidelines
--

Chairpersons: M. Imazio, (Turin, IT), A. Ristić, (Belgrade, RS)

Acute pericarditis	M. Imazio, Turin, IT
Prevention of recurrent pericarditis with colchicine in 2013	Y. Adler, Ramat Gan, IL
Pericardial effusion and cardiac tamponade	A. Ristić, Belgrade, RS
Constrictive pericarditis	W. Tomkowski, Warsaw, PL

Congress adjourn 19:00

Friday, Oct 25th - Saturday, Oct 26th
--

Posters Presentation – Auditorium Meridian

#	Title	Author
1	Normal ECG associates benign clinical profile in HCM	M. J. Antolin Perez,

AGENDA

		Faro, PT
<u>2</u>	Inverted-takotsubo pattern cardiomyopathy: a unique presentation of diabetic ketoacidosis	A. Castro, Penafiel, PT
<u>3</u>	Recurrent pericarditis: the role of CMR	A. Gandino, Milan, IT
<u>4</u>	Identification of two genetic variants with NGS: catecholaminergic monomorphic ventricular tachycardia and left ventricular non-compaction	E. Garcia-Molina, Murcia, SP
<u>5</u>	A case of takotsubo cardiomyopathy (apical ballooning syndrome) immediately after thyroidectomy	Hsiao-Liang Cheng, Taipei, TW
<u>6</u>	Assessment of left ventricular systolic function by the use of speckle-tracking echocardiography in patients with inflammatory and dilated cardiomyopathy	S. Cherniuk, Kiev, UA
<u>7</u>	Clinical characteristics of atypical pattern in takotsubo cardiomyopathy	Byung Hyun Joe, Seoul, KR
<u>8</u>	Increased heart Rate with sleep disordered breathing in hypertrophic cardiomyopathy	T. Konecny, Rochester (MN), USA
<u>9</u>	Malignant ventricular tachycardia associated with SCN5A gene variant.	A. Kostareva, St. Petersburg, RU
<u>10</u>	Viral infection and dilated cardiomyopathy today	T. Kurushka, Minsk, BY
<u>11</u>	Arrhythmic outcomes in arrhythmogenic cardiomyopathy with implantable cardioverter defibrillator	J. Lopez-Ayala, Murcia, SP
<u>12</u>	Delayed graft dysfunction after cardiac transplantation.	I. Málek, Prague, CZ
<u>1</u>	Yield of genetic testing in a Portuguese hypertrophic cardiomyopathy	I. Cruz,

AGENDA

3	population: a multicenter study	Faro, PT
1 4	Predictors of atrial fibrillation in patients with hypertrophic cardiomyopathy: a multicenter Portuguese study	O. Azevedo, Faro, PT
1 5	Predictors of in-hospital outcome in takotsubo cardiomyopathy – a multicenter study	O. Azevedo, Faro, PT
1 6	In-hospital and medium term prognosis of takotsubo cardiomyopathy – a multicenter study	N. Marques, Faro, PT
1 7	Predictors of outcome in takotsubo cardiomyopathy – a multicenter study	A.R. Almeida, Faro, PT
1 8	Trying to compact the evidence about left ventricular noncompaction	D. Moreira, Faro, PT
1 9	Importance of bioinformatic studies as a complementary tool in the classification of desmosomal variants	I. Milanés, Murcia, SP
2 0	X- linked hypertrophic cardiomyopathy caused by a novel mutation in FHL1.	M. Navarro Penalver, Murcia, SP
2 1	Left-sided progression of arrhythmogenic cardiomyopathy mimicking acute myocarditis in patients with Naxos cardiocutaneous syndrome	A. Protonotarios, Naxos, GR
2 2	Causes of sudden death in the region of Murcia (Pheidippides study).	C. Ruescas, Murcia, SP
2 3	Description of a novel mutation in MYBPC3 gene causing Hypertrophic Cardiomyopathy	M. Sabater-Molina, Murcia, SP
2 4	First description of Fabry cardiomyopathy associating short PR with delta waves	I. San Román Monserrat, Murcia, SP
2 5	Renin-angiotensin-aldosterone system (RAAS) and severity of left ventricular hypertrophy in Hypertrophic Cardiomyopathy.	I. Sánchez, Murcia, SP
2 6	Two novel mutations in exon 1 of the alpha-galactosidase A gene – the first results of a screening program for Fabry disease in patients with left ventricular hypertrophy in Slovakia.	P. Solik, Bratislava, SK

AGENDA

2 7	Echocardiographic evaluation of hypertensive patients with left ventricular hypertrophy	R. Stolic, K.Mitrovic a, RS
2 8	Role of FDG-PET to predict reversibility of transient constrictive pericarditis: initial results	Chang Sung-A, Seoul, KR
2 9	Echocardiographic Change of Tuberculosis Pericarditis during Steroid therapy: Serial echocardiographic follow-up study	Chang Sung-A, Seoul, KR
3 0	The MYH7, MYBPC genes mutations in patients with hypertrophic cardiomyopathy in the republic of Belarus	S. Komissaro va, Minsk, BY
3 1	Myocarditis – dynamic changes assessed by cardiovascular magnetic resonance	J. Šedivý, Pilsen, CZ
3 2	Prevalence and clinical significance of heart failure symptoms in patients with nonobstructive HCM	B. Tomberli, Florence, IT
3 3	Outcome of hypertrophic cardiomyopathy associated with sarcomere protein gene mutations: impact of the Implantable cardioverter-defibrillator	B. Tomberli, Florence, IT
3 4	Survival of chemotherapy-induced cardiomyopathy in the last two decades	B. Tomberli, Florence, IT
3 5	Viral infection and prognostic predictors of poor clinical outcomes in patients with dilated cardiomyopathy	T. Vaikhansk aya, Minsk, BY
3 6	The case of severe idiopathic dilated cardiomyopathy associated with new LMNA mutation and malignant arrhythmias	T. Vaikhansk aya, Minsk, BY
3 7	Microvolt T-wave alternation as risk marker of ventricular tachyarrhythmias events in patients with dilated cardiomyopathy	T. Vaikhansk aya, Minsk, BY
3	Microvolt T-wave alternation for risk-prediction of ventricular	T.

AGENDA

8 tachyarrhythmic events in patients with nonischemic dilated cardiomyopathy and ICD

Vaikhansk
aya,
Minsk, BY

**3 Myocardial fibrosis in cardiac magnetic resonance imaging predicts clinical
9 presentation and outcome in children with hypertrophic cardiomyopathy.**

L.
Ziolkowsk
a,
Warsaw,
PL
